SGP Earnings Date: Nov 5, 2026 (Estimated) — SpyGlass Pharma, Inc. Common Stock
NASDAQ
Updated
When is SGP's next earnings date?
SpyGlass Pharma, Inc. Common Stock (SGP) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 9:02 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.66.
How did SGP do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), SpyGlass Pharma, Inc. Common Stock posted EPS of -$0.59 versus the -$0.51 estimate, a miss of 11.3%. Revenue was $0. The stock's 1-day post-earnings move was +2.3%.
How much does SGP stock move after earnings?
SGP beat EPS estimates in 0 of its last 2 reported quarters. Over the last 3 reports the stock moved an average of 5.6% (up or down) in the day after earnings.
About SpyGlass Pharma, Inc. Common Stock
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.51 | -0.59 | -11.32% | $0 | ❌ Miss | +2.26% | +1.70% | +16.93% |
| 2026-05-14 | Q1 2026 | -0.42 | -0.69 | -64.29% | $0 | ❌ Miss | -4.37% | -9.15% | -21.96% |
| 2026-03-26 | Q4 2025 | — | -5.72 | — | $0 | — | -10.28% | -10.87% | -6.15% |
Showing last 3 quarters.